BioVie Inc. (NASDAQ: BIVI) completed the last patient evaluation visit for its SUNRISE-PD Phase 2 trial testing bezisterim in early-stage ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE